临床心身疾病杂志
臨床心身疾病雜誌
림상심신질병잡지
JOURNAL OF CLINICAL PSYCHOSOMATIC DISEASES
2013年
6期
556-559
,共4页
精神分裂症%齐拉西酮%利培酮%氯丙嗪%认知功能%阳性与阴性症状量表%数字划消测验%修订韦氏成人记忆量表%副反应量表
精神分裂癥%齊拉西酮%利培酮%氯丙嗪%認知功能%暘性與陰性癥狀量錶%數字劃消測驗%脩訂韋氏成人記憶量錶%副反應量錶
정신분렬증%제랍서동%리배동%록병진%인지공능%양성여음성증상량표%수자화소측험%수정위씨성인기억량표%부반응량표
Schizophrenia%ziprasidone%risperidone%chlorpromazine%cognitive function%PANSS%CT%WM S-RC%TESS
目的：探讨齐拉西酮、利培酮和氯丙嗪治疗对首发精神分裂症患者认知功能的影响。方法将96例首发精神分裂症患者随机分成3组，每组32例，分别口服齐拉西酮、利培酮和氯丙嗪治疗，观察8周。于治疗前后采用阳性与阴性症状量表评定临床疗效，副反应量表评定不良反应，威斯康星卡片分类测验、数字划消测验和修订韦氏成人记忆量表评定认知功能。结果治疗8周末齐拉西酮组总有效率为86．67％，利培酮组为83．33％，氯丙嗪组为85．71％，3组总有效率比较差异无显著性（P＞0．05）；齐拉西酮组、利培酮组认知功能各项测验指标均较治疗前有显著改善（P＜0．01），氯丙嗪组则无显著变化（P＞0．05）；齐拉西酮组和利培酮组不良反应发生率显著低于氯丙嗪组（P＜0．05）。结论齐拉西酮、利培酮和氯丙嗪治疗首发精神分裂症疗效显著且相当，但齐拉西酮和利培酮能改善患者的认知功能，安全性更高，显著优于氯丙嗪治疗。
目的：探討齊拉西酮、利培酮和氯丙嗪治療對首髮精神分裂癥患者認知功能的影響。方法將96例首髮精神分裂癥患者隨機分成3組，每組32例，分彆口服齊拉西酮、利培酮和氯丙嗪治療，觀察8週。于治療前後採用暘性與陰性癥狀量錶評定臨床療效，副反應量錶評定不良反應，威斯康星卡片分類測驗、數字劃消測驗和脩訂韋氏成人記憶量錶評定認知功能。結果治療8週末齊拉西酮組總有效率為86．67％，利培酮組為83．33％，氯丙嗪組為85．71％，3組總有效率比較差異無顯著性（P＞0．05）；齊拉西酮組、利培酮組認知功能各項測驗指標均較治療前有顯著改善（P＜0．01），氯丙嗪組則無顯著變化（P＞0．05）；齊拉西酮組和利培酮組不良反應髮生率顯著低于氯丙嗪組（P＜0．05）。結論齊拉西酮、利培酮和氯丙嗪治療首髮精神分裂癥療效顯著且相噹，但齊拉西酮和利培酮能改善患者的認知功能，安全性更高，顯著優于氯丙嗪治療。
목적：탐토제랍서동、리배동화록병진치료대수발정신분렬증환자인지공능적영향。방법장96례수발정신분렬증환자수궤분성3조，매조32례，분별구복제랍서동、리배동화록병진치료，관찰8주。우치료전후채용양성여음성증상량표평정림상료효，부반응량표평정불량반응，위사강성잡편분류측험、수자화소측험화수정위씨성인기억량표평정인지공능。결과치료8주말제랍서동조총유효솔위86．67％，리배동조위83．33％，록병진조위85．71％，3조총유효솔비교차이무현저성（P＞0．05）；제랍서동조、리배동조인지공능각항측험지표균교치료전유현저개선（P＜0．01），록병진조칙무현저변화（P＞0．05）；제랍서동조화리배동조불량반응발생솔현저저우록병진조（P＜0．05）。결론제랍서동、리배동화록병진치료수발정신분렬증료효현저차상당，단제랍서동화리배동능개선환자적인지공능，안전성경고，현저우우록병진치료。
Objective To explore the influence of ziprasidone ,risperidone and chloropromazine on cogni-tive function of first-episode schizophrenics .Methods Ninety-six patients with first-episode schizophrenia were assigned to three groups (n=32) receiving ziprasidone ,risperidone or chlorpromazine for 8 weeks . Efficacies were assessed with the Positive and Negative Syndrome Scale (PANSS ) and adverse reactions with the Treatment Emergent Symptom Scale (TESS) at baseline and at the end of the 8th week ,and cog-nitive functions with the Wisconsin Card Sorting Test (WCST ) ,Cancellation Test (CT ) and Wechsler Memory Scale revised in China (WMS-RC) .Results At the end of the 8th week total effective rate was re-spectively 86 .67% in ziprasidone ,83 .33% in risperidone and 85 .71% in chlorpromazine group ,which showed no significant differences (P>0 .05);each testing index of cognitive function improved more nota-bly in both ziprasidone and risperidone group compared with pretreatment (P<0 .01) ,there were no nota-ble changes in those indexes in chlorpromazine group (P>0 .05);the incidences of adverse reactions were significantly lower in ziprasidone and risperidone than chlorpromazine group (P<0 .05) .Conclusion Ziprasidone ,risperidone and chloropromazine have an evident and equivalent effect in the treatment of first-episode schizophrenia ,but ziprasidone and risperidone could improve patients’ cognitive function and has higher safety compared with chlorpromazine treatment .
